Keyword: University of Oxford
European researchers discovered how drugs bind to the enzyme DHODH, which could lead to more selective cancer drugs.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.
Takeda Pharmaceutical has teamed up with Harrington Discovery Institute to support research into treatments for rare diseases.
In this week's EuroBiotech Report, Europe-wide scrap for EMA intensifies, Vifor goes solo post-IPO, Mission bags Fox funding and more.
Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.
Novo Nordisk has committed £115 million ($144 million) to set up a Type 2 diabetes drug discovery center at the University of Oxford.
OxSonics and its sister company have raised $11 million to take ultrasound-based technologies into clinical development.
Evotec and the University of Oxford have teamed up to bridge the gap between academic research and industry.
Our EuroBiotech roundup this week features a pair of IPOs, the takeover of Alizé Pharma II and advance of Galapagos' CF pipeline.
A clutch of Oxford-based spinouts raise money, Big Pharma-backed Merus hits go on IPO and Vifor pays $110M for two assets.